Radiopharm Theranostics Limited (RADX), on Monday announced promising new data from the European Molecular Imaging Meeting or EMIM 2025, showcasing the potential of 68Ga-RAD202 for imaging and 177Lu-RAD202 for therapy in HER2-positive solid tumors.
HER2-positive cancers, such as certain types of breast cancer, are aggressive and often have limited treatment options.
RAD202 represents a novel approach targeting the HER2 receptor using radiopharmaceuticals.
The data revealed that 68Ga-RAD202 effectively binds to HER2 in tumors, demonstrating high tumor-to-background ratios in imaging, with low uptake in non-target organs, except for the bladder and kidneys, as expected.
Furthermore, 177Lu-RAD202 therapy resulted in a significant reduction in tumor volume and improved survival rates, with fractionated dosing proving more effective than a single-dose regimen.
Key findings include:
--- 68Ga-RAD202 showed specific accumulation in HER2-positive tumors, enhancing imaging with a favorable tumor-to-organ ratio.
-- Treatment with 177Lu-RAD202 led to tumor volume reduction and extended survival, with fractionated dosing being more effective than single-dose therapy.
-- The data further supports the ongoing Phase 1 trial of 177Lu-RAD202 in HER2-positive advanced solid tumors, currently recruiting patients in Australia.
These findings underscore the potential of RAD202 to provide a novel treatment option for patients with HER2-positive cancers, especially those who have not responded to or cannot tolerate current therapies.
Currently, RADX is trading at $6.29 up by 8.45 percent on the Nasdaq.
For comments and feedback contact: editorial@rttnews.com
Business News
May 15, 2026 15:25 ET Apart from the confirmation of Kevin Warsh as the next Fed chair, the main news on the economics front this week included key price data from the U.S. and the first quarter economic growth figures from major economies. Both consumer prices and producer costs have started to reflect the effect of supply shocks due to the Middle East conflict. In Europe, GDP data was in focus, while inflation data from China dominated the news flow in Asia.